[Palifermin in the preventive treatment of oral mucositis in autograft patients: data on efficacy and tolerance following marketing approval].
BACKGROUND
Few data are available on the efficacy of and tolerance to palifermin in the preventive treatment of oral mucositis in autograft patients treated with conditioning protocols usually used in France.


METHODS
Our retrospective study bears on the first five candidates for autograft who benefited from prophylactic treatment with palifermin (60 microg/kg/day) between December 2005 and March 2006.


RESULTS
Despite the prophylactic treatment, 3 patients developed severe oral mucositis. Moreover, in 3 patients, palifermin was found to be responsible for the onset of severe toxidermia, which required, in 2 cases, interruption of the treatment.


CONCLUSIONS
These results need to be confirmed by a larger study that would also make it possible to evaluate the impact of palifermin on morbi-mortality in autograft patients in France, and to determine the safety profile of this drug.
Onteniente
Sylvain
S
Service Pharmacie, Hôpital du Bocage, CHU Dijon, Dijon, France. onteniente.sylvain@voila.fr
Coullet
Valérie
V
Chemelle
Mathilde
M
Lafont
Ingrid
I
Pernot
Corinne
C
Guignard
Marie-Hélène
MH
D000368:Aged; D017690:Cell Transplantation; D003875:Drug Eruptions / Q000473:pathology; D005260:Female; D051523:Fibroblast Growth Factor 7 / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications / Q000628:therapy; D012189:Retrospective Studies; D013280:Stomatitis / Q000209:etiology* / Q000517:prevention & control*; D014182:Transplantation, Autologous
D051523:Fibroblast Growth Factor 7